JG
PGNX

Jefferies Group’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Jefferies Group’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-22,081
Closed -$136K – 3208
2019
Q2 		$136K Buy
22,081
+2,981
+16% +$14.4K ﹤0.01% 2233
2019
Q1 		$89K Buy
+19,100
New +$86.4K ﹤0.01% 2135
2014
Q4 		– Sell
-75,000
Closed -$389K – 2475
2014
Q3 		$389K Sell
75,000
-55,000
-42% -$274K ﹤0.01% 1448
2014
Q2 		$560K Buy
+130,000
New +$496K ﹤0.01% 1178
2014
Q1 		– Sell
-155,900
Closed -$831K – 2492
2013
Q4 		$831K Buy
155,900
+120,900
+345% +$532K 0.01% 917
2013
Q3 		$176K Buy
+35,000
New +$190K ﹤0.01% 1639

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Jefferies Group's PGNX Position: Q3 2019 in Review

Jefferies Group sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2019, closing a stake of 22,081 shares — an estimated $136K sold.

Jefferies Group first reported a position in PGNX in Q3 2013 and held it in 6 quarters. The position peaked at $831K in Q4 2013. 135 funds tracked by Wall St. Rank hold PGNX as of Q3 2019.

  • Jefferies Group reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2019 after selling out during the quarter.
  • Jefferies Group sold 22,081 Progenics Pharmaceuticals Inc shares in Q3 2019, an estimated $136K.
  • Jefferies Group first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 6 quarters.
  • Jefferies Group's Progenics Pharmaceuticals Inc position peaked at $831K in Q4 2013.
  • 135 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.